Focused On-demand Library for Vasoactive intestinal polypeptide receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Pituitary adenylate cyclase-activating polypeptide type II receptor; VPAC1

Alternative UPACC:

P32241; A5JUT9; B3KPV1; B4DEB5; B4DGI4; F5H1F5; G3V0I1; Q15871; Q6P2M6


Vasoactive intestinal polypeptide receptor 1 (VIPR1), also known as VPAC1, is a critical receptor that binds vasoactive intestinal polypeptide (VIP) with high affinity. Its activity is mediated through G proteins that activate adenylyl cyclase, leading to increased levels of cyclic AMP. VIPR1 shows a preference for VIP over pituitary adenylate cyclase-activating polypeptide (PACAP-27 and PACAP-38), highlighting its specificity in cellular signaling pathways.

Therapeutic significance:

Understanding the role of Vasoactive intestinal polypeptide receptor 1 could open doors to potential therapeutic strategies. Its involvement in cyclic AMP signaling pathways suggests its potential impact on diseases where these pathways are dysregulated. Exploring VIPR1's functions and interactions could lead to novel treatments for such conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.